News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

30 September 2008 CSL Behring Initiating Next Round of LEAD Grants to Support Patient Advocacy Efforts

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is soliciting grants to support patient access to care through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program is committed to funding grassroots advocacy efforts in the United States by providing grants to patient organizations dedicated to helping people with rare diseases who use plasma-derived or recombinant therapies to manage their conditions.

> Read More
25 September 2008 Data Published in Journal of Clinical Immunology Show Privigen™ Demonstrates Effectiveness and Tolerability in Patients with Primary Immunodeficiencies

New L-Proline Stabilized Immune Globulin Intravenous (Human) 10 Percent Liquid can be stored at room temperature, offering convenience to healthcare professionals

> Read More
22 August 2008 CSL Behring’s Innovative HeliTraxSM System

Hemophilia A patients who use Helixate® FS, Antihemophilic Factor (Recombinant), and their treatment providers are now tracking treatment progress in real time, thanks to the HeliTraxSM System, a state-of-the-art wireless Internet-based data management system recently introduced by CSL Behring.

> Read More
18 August 2008 CSL Behring Provides $1.2M Grant for World's First Study of Postpartum Women with VWD, Common Bleeding Disorder

CSL Behring is providing a $1.2 million grant to fund a first-of-its kind, nationwide study that when completed could serve as the basis for determining optimal prophylaxis treatment for postpartum women with von Willebrand disease (VWD). Investigators anticipate that the study results will produce a better understanding of the physiology of VWD in the postpartum period, whether treatment is needed and, if so, for how long.

> Read More
21 July 2008 CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding

CSL Behring announced today that it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval to market its human fibrinogen concentrate in the United States for the treatment of congenital fibrinogen deficiency, a rare bleeding disorder resulting from deficiency of fibrinogen.

> Read More
Page 50 of 54 First | Previous | Next | Last

LinkedIn Twitter Facebook Google+